Monday, 21 September 2026European Markets

VISTIN PHARMA Stock Went Up By Over 12% At Session Start On Friday

Loading stream...

(VIANEWS) - Shares of VISTIN PHARMA (Oslo Børs All-share Index_GI: VISTN.OL) jumped by a staggering 12.91% to kr18.80 at 10:41 EST on Friday, following the last session's upward trend. Oslo Børs All-share Index_GI is sliding 0.78% to kr1,405.92, after five consecutive sessions in a row of losses. This seems, as yet, a somewhat down trend trading session today.

About VISTIN PHARMA

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin hydrochloride APIs and direct compressive granulates for the pharmaceutical industry. The company was incorporated in 2015 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.96.

PE Ratio

VISTIN PHARMA has a trailing twelve months price to earnings ratio of 19.58. Meaning, the purchaser of the share is investing kr19.58 for every norwegian krone of annual earnings.

Volume

Today's last reported volume for VISTIN PHARMA is 58691 which is 298.95% above its average volume of 14711.

Volatility

VISTIN PHARMA's last week, last month's, and last quarter's current intraday variation average was a negative 0.61%, a negative 0.13%, and a positive 2.18%.

VISTIN PHARMA's highest amplitude of average volatility was 2.76% (last week), 1.15% (last month), and 2.18% (last quarter).

More news about VISTIN PHARMA (VISTN.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com